Table 1.

Main patient characteristics and joint bleeding phenotype

	N=270
Age at last follow-up, mean (SD), y	45.6 (19.9)
FVIII:C, mean (SD), IU/dL∗	23.5 (12.1)
Time of observation for other bleeds, mean (SD), y†	13.4 (3.8)
No zero blood group, n (%)‡	115 (59.9)
All joint bleeding episodes
At least 1 joint bleeding episode in life, n (%)	100 (37)
At least 1 joint bleeding episode in the 1st quartile of age (<28), n (%)§	60 (22.6)
At least 1 joint bleeding episode in the 2nd quartile of age (28 ≤ x < 45), n (%)‖	25 (12.3)
At least 1 joint bleeding episode in the 3rd quartile of age (45 ≤ x < 59), n (%)¶	10 (7.7)
At least 1 joint bleeding episode in the 4th quartile of age (≥59), n (%)#	14 (21.2)
Spontaneous joint bleeding episodes
At least 1 spontaneous joint bleeding episode in life, n (%)∗∗	10 (4.2)
At least 1 spontaneous joint bleeding episode in the 1st quartile of age (<28), n (%)††	3 (1.3)
At least 1 spontaneous joint bleeding episode in the 2nd quartile of age (28 ≤ x < 45), n (%)‡‡	3 (1.7)
At least 1 spontaneous joint bleeding episode in the 3rd quartile of age (45 ≤ x < 59), n (%)§§	0
At least 1 spontaneous joint bleeding episode in the 4th quartile of age (≥59), n (%)‖‖	3 (5.4)

FVIII:C, factor VIII coagulant activity.

^∗For each patient, the mean level of all the FVIII:C dosages performed in life by 1 stage clotting assay.

^†For each patient, the period between January 2005 and the date of last follow-up. This time of observation was considered for other than joint bleeds. For joint bleeds we considered as time of observation the whole life (age at last follow-up).

^‡Available in 192 patients.

^§Available in 266 patients.

^‖Available/applicable in 203 patients.

^¶Available/applicable in 130 patients.

^#Available/applicable in 66 patients.

^∗∗Available in 240 patients.

^††Available in 238 patients.

^‡‡Available/applicable in 180 patients.

^§§Available/applicable in 115 patients.

^‖‖Available/applicable in 56 patients.